Literature DB >> 33219525

Diagnostic Accuracy of Amyloid versus 18 F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia.

Orit H Lesman-Segev1,2, Renaud La Joie1, Leonardo Iaccarino1, Iryna Lobach3, Howard J Rosen1, Sang Won Seo4, Mustafa Janabi5, Suzanne L Baker5, Lauren Edwards1, Julie Pham1, John Olichney6, Adam Boxer1, Eric Huang1, Marilu Gorno-Tempini1, Charles DeCarli6, Mackenzie Hepker1, Ji-Hye L Hwang1, Bruce L Miller1, Salvatore Spina1, Lea T Grinberg1, William W Seeley1, William J Jagust5,7, Gil D Rabinovici1,4,6,8.   

Abstract

OBJECTIVE: The purpose of this study was to compare the diagnostic accuracy of antemortem 11 C-Pittsburgh compound B (PIB) and 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus autopsy diagnosis in a heterogenous sample of patients.
METHODS: One hundred one participants underwent PIB and FDG PET during life and neuropathological assessment. PET scans were visually interpreted by 3 raters blinded to clinical information. PIB PET was rated as positive or negative for cortical retention, whereas FDG scans were read as showing an Alzheimer disease (AD) or non-AD pattern. Neuropathological diagnoses were assigned using research criteria. Majority visual reads were compared to intermediate-high AD neuropathological change (ADNC).
RESULTS: One hundred one participants were included (mean age = 67.2 years, 41 females, Mini-Mental State Examination = 21.9, PET-to-autopsy interval = 4.4 years). At autopsy, 32 patients showed primary AD, 56 showed non-AD neuropathology (primarily frontotemporal lobar degeneration [FTLD]), and 13 showed mixed AD/FTLD pathology. PIB showed higher sensitivity than FDG for detecting intermediate-high ADNC (96%, 95% confidence interval [CI] = 89-100% vs 80%, 95% CI = 68-92%, p = 0.02), but equivalent specificity (86%, 95% CI = 76-95% vs 84%, 95% CI = 74-93%, p = 0.80). In patients with congruent PIB and FDG reads (77/101), combined sensitivity was 97% (95% CI = 92-100%) and specificity was 98% (95% CI = 93-100%). Nine of 24 patients with incongruent reads were found to have co-occurrence of AD and non-AD pathologies.
INTERPRETATION: In our sample enriched for younger onset cognitive impairment, PIB-PET had higher sensitivity than FDG-PET for intermediate-high ADNC, with similar specificity. When both modalities are congruent, sensitivity and specificity approach 100%, whereas mixed pathology should be considered when PIB and FDG are incongruent. ANN NEUROL 2021;89:389-401.
© 2020 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33219525      PMCID: PMC7856004          DOI: 10.1002/ana.25968

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

1.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

Authors:  C J Galton; K Patterson; J H Xuereb; J R Hodges
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Authors:  Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-08       Impact factor: 9.236

4.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Authors:  Rik Ossenkoppele; Daniel R Schonhaut; Michael Schöll; Samuel N Lockhart; Nagehan Ayakta; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Andreas Lazaris; Averill Cantwell; Jacob Vogel; Miguel Santos; Zachary A Miller; Brianne M Bettcher; Keith A Vossel; Joel H Kramer; Maria L Gorno-Tempini; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2016-03-08       Impact factor: 13.501

5.  Frontotemporal dementia: clinicopathological correlations.

Authors:  Mark S Forman; Jennifer Farmer; Julene K Johnson; Christopher M Clark; Steven E Arnold; H Branch Coslett; Anjan Chatterjee; Howard I Hurtig; Jason H Karlawish; Howard J Rosen; Vivianna Van Deerlin; Virginia M-Y Lee; Bruce L Miller; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

6.  The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.

Authors:  Natalie L Marchant; Bruce R Reed; Nerses Sanossian; Cindee M Madison; Stephen Kriger; Roxana Dhada; Wendy J Mack; Charles DeCarli; Michael W Weiner; Dan M Mungas; Helena C Chui; William J Jagust
Journal:  JAMA Neurol       Date:  2013-04       Impact factor: 18.302

7.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

8.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.

Authors:  Sang Won Seo; Nagehan Ayakta; Lea T Grinberg; Sylvia Villeneuve; Manja Lehmann; Bruce Reed; Charles DeCarli; Bruce L Miller; Howard J Rosen; Adam L Boxer; James P O'Neil; Lee-Way Jin; William W Seeley; William J Jagust; Gil D Rabinovici
Journal:  Neuroimage Clin       Date:  2016-11-11       Impact factor: 4.881

9.  Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain.

Authors:  Rik Ossenkoppele; Leonardo Iaccarino; Daniel R Schonhaut; Jesse A Brown; Renaud La Joie; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Joel H Kramer; Maria-Luisa Gorno-Tempini; Bruce L Miller; Howard J Rosen; William W Seeley; William J Jagust; Gil D Rabinovici
Journal:  Neuroimage Clin       Date:  2019-05-02       Impact factor: 4.881

10.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.

Authors:  Alan J Thomas; Johannes Attems; Sean J Colloby; John T O'Brien; Ian McKeith; Rodney Walker; Lean Lee; David Burn; Debra J Lett; Zuzana Walker
Journal:  Neurology       Date:  2016-12-09       Impact factor: 9.910

View more
  3 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

Review 2.  The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.

Authors:  Marianne Chapleau; Leonardo Iaccarino; David Soleimani-Meigooni; Gil D Rabinovici
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

Review 3.  Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology.

Authors:  Bradley T Peet; Salvatore Spina; Nidhi Mundada; Renaud La Joie
Journal:  Neurotherapeutics       Date:  2021-08-13       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.